sinc
discoveri
tool
gene
transfer
vector
deriv
adenoassoci
viru
aav
use
gene
therapi
applic
attract
scientist
field
except
properti
effici
vivo
gene
transfer
level
durat
transgen
express
mani
year
aav
consid
low
immunogen
vector
due
abil
induc
longterm
express
nonselfprotein
contrast
observ
viral
vector
adenoviru
strong
immun
respons
transgen
product
document
perceiv
low
immunogen
like
explain
use
aav
vector
vaccin
serious
consid
earli
inde
analys
conduct
use
varieti
transgen
anim
speci
slowli
chang
vision
immunolog
properti
aav
increas
number
studi
also
perform
field
vaccin
even
comparison
mode
vaccin
system
perform
analys
conduct
far
field
activ
immunotherapi
strongli
suggest
aav
possess
interest
featur
use
tool
produc
effici
sustain
antibodi
respons
addit
recent
studi
also
highlight
potenti
aav
passiv
immunotherapi
review
summar
main
studi
conduct
evalu
potenti
aav
vector
vaccin
infecti
agent
discuss
advantag
drawback
altogeth
varieti
studi
conduct
field
contribut
understand
immunolog
properti
versatil
viru
definit
possibl
futur
applic
histor
vaccin
strategi
infecti
agent
mostli
use
live
attenu
pathogen
vaccin
highli
effici
gener
humor
cellular
immun
respons
mani
pathogen
approach
riski
even
attenu
form
use
human
subunit
vaccin
usual
recombin
protein
provid
interest
safe
altern
howev
use
limit
gener
antibodi
ab
respons
therefor
limit
prevent
vaccin
strategi
pathogen
effici
clear
humor
respons
addit
effici
frequent
requir
repeat
inject
high
dose
vaccin
coupl
adjuv
context
develop
viral
vector
provid
interest
altern
sinc
effici
deliv
antigen
ag
antigen
process
pathway
lead
stimul
cytotox
cell
respons
essenti
clear
intracellular
pathogen
develop
therapeut
vaccin
viral
vector
deriv
wild
type
virus
delet
part
viral
gene
immunogen
properti
viral
vector
result
ag
express
also
intrins
biolog
properti
viral
particl
determin
interact
cell
immun
system
particular
antigen
present
cell
apc
target
tissu
contribut
natur
potenc
immun
respons
induc
far
wide
evalu
viral
vector
vaccin
particular
human
clinic
trial
deriv
adenoviru
ad
poxviru
famili
type
vector
provid
sever
advantag
vaccin
effici
infect
sever
cell
type
includ
apc
howev
use
vaccin
type
vector
contain
addit
transgen
encod
ag
sever
viral
gene
whose
express
constitut
safeti
concern
lower
modifi
efficaci
vaccin
divert
immun
respons
ag
addit
vector
type
strong
immunogen
viral
particl
may
seen
help
induc
strong
immun
respons
also
constitut
safeti
problem
due
strong
inflammatori
respons
induc
last
least
mani
viral
vector
main
issu
preexist
immun
human
popul
may
constitut
barrier
use
man
adenoassoci
viru
aav
vector
alreadi
rel
long
histori
gene
therapi
recent
emerg
vaccin
field
sinc
first
uniqu
report
man
et
al
document
capac
aav
induc
strong
humor
cellular
respons
herp
simplex
viru
hsv
type
glycoprotein
b
increas
number
studi
explor
use
aav
vector
genet
vaccin
thu
contribut
understand
immunolog
properti
review
focus
descript
vaccin
studi
conduct
mostli
viral
microbi
antigen
use
aav
vector
directli
vivo
highlight
properti
potenti
limit
futur
develop
neither
studi
use
aav
vector
vaccin
noninfecti
diseas
use
vector
immunotherapi
ex
vivo
gene
transfer
dendrit
cell
dc
includ
two
first
section
summar
main
characterist
aav
vector
use
variou
vaccin
set
third
section
present
result
advanc
studi
explor
potenti
aav
vaccin
experiment
challeng
relev
anim
model
andor
explor
efficaci
aavmedi
vaccin
nonhuman
primat
nhp
final
last
part
review
describ
like
futur
develop
field
compar
virus
use
vector
vaccin
particular
ad
poxvirus
aav
potenti
offer
signific
number
advantag
first
vector
deriv
nonpathogen
viru
inher
replic
defect
accordingli
sever
preclin
clinic
gene
therapi
trial
demonstr
favor
safeti
profil
vector
gutless
therefor
encod
viral
gene
vector
genom
usual
compos
singlestrand
ss
dna
molecul
contain
transgen
express
cassett
flank
viral
invert
termin
repeat
review
see
ref
aav
particl
contain
doublestrand
also
call
selfcomplementari
sc
aav
genom
also
develop
improv
kinet
level
express
transgen
aav
vector
possess
capac
effici
transduc
sever
tissu
vivo
isol
sever
aav
serotyp
multitud
capsid
variant
potenti
offer
possibl
develop
primeboost
strategi
switch
aav
capsid
thu
avoid
anticapsid
neutral
humor
respons
induc
first
inject
howev
viral
vector
system
aav
also
number
drawback
notabl
limit
transgen
capac
strong
wide
preexist
immun
human
technolog
challeng
produc
larg
high
titter
vector
stock
studi
conduct
field
activ
vaccin
use
aav
vector
divers
term
target
object
strategi
tabl
howev
far
limit
number
studi
conduct
directli
compar
aav
vector
vector
vaccin
despit
divers
lack
compar
studi
sever
common
conclus
extrapol
studi
defin
advantag
also
pitfal
aav
vector
particular
applic
initi
analys
conduct
field
vaccin
perform
use
vector
despit
lower
effici
compar
aav
serotyp
initi
studi
vector
alreadi
demonstr
capac
induc
strong
immun
respons
use
varieti
inject
rout
viral
ag
tabl
notabl
studi
use
vector
express
sever
simian
immunodefici
viru
siv
gene
indic
singl
intramuscular
administr
vector
abl
elicit
sivspecif
cell
ab
demonstr
potenti
macaqu
nhp
model
thereaft
aav
serotyp
rapidli
enter
field
outperform
term
immun
respons
expect
higher
effici
gene
transfer
use
variou
aav
serotyp
also
allow
vari
inject
rout
tabl
particular
sever
studi
use
vector
intranas
vaccin
induc
mucos
immun
notabl
nasal
applic
effici
even
presenc
high
level
preexist
serum
neutral
antibodi
nab
frontier
immunolog
microbi
immunolog
prevent
reimmun
serotyp
transgen
express
remark
featur
aav
vector
vaccin
studi
capac
induc
strong
long
last
ab
respons
even
singl
administr
sever
studi
document
induct
humor
respons
last
mani
month
sometim
year
addit
studi
aavinduc
ab
respons
higher
sustain
use
vaccin
strategi
includ
dna
recombin
protein
inactiv
viru
viruslik
particl
vlp
pronounc
ab
respons
may
link
high
sustain
express
transgen
time
achiev
aav
serotyp
high
long
last
level
ab
respons
may
also
explain
instanc
boost
effect
alway
observ
upon
reinject
altern
aav
serotyp
contrast
studi
document
possibl
enhanc
aavinduc
humor
respons
use
ad
vector
express
ag
boost
observ
suggest
enhanc
humor
respons
achiev
stimul
differ
immun
pathway
use
initi
prime
vaccin
scenario
similar
describ
vaccin
strategi
use
plasmid
dna
prime
inject
heterolog
vaccin
boost
control
sever
infecti
diseas
requir
addit
strong
humor
respons
concomit
induct
cytotox
cellular
respons
prevent
viru
spread
also
erad
virusinfect
cell
sinc
first
report
use
aav
vaccin
sever
studi
document
induct
transgenespecif
tcell
respons
follow
inject
aav
vector
mice
nhp
howev
two
studi
thoroughli
analyz
cellular
respons
quantit
qualit
two
report
publish
indic
tcell
respons
induc
aav
vector
deriv
varieti
natur
aav
serotyp
fail
success
recal
amplifi
upon
boost
ad
vector
indic
default
tcell
memori
respons
detail
analys
respons
show
cell
marker
exhaust
correl
continu
express
transgen
whether
persist
transgen
express
consequ
caus
function
impair
tcell
respons
still
unclear
interestingli
howev
function
transgenespecif
tcell
respons
could
induc
chang
aav
capsid
hybrid
capsid
deriv
two
natur
rhesu
macaqu
isol
abl
gener
tcell
respons
transgen
product
mice
nhp
could
success
amplifi
follow
boost
ad
vector
studi
conduct
mice
demonstr
intramuscular
administr
vector
abl
induc
strong
cellular
respons
even
transgen
product
lacz
usual
toler
use
natur
aav
serotyp
result
elimin
aavtransduc
cell
within
month
aav
administr
altogeth
analys
indic
capsid
addit
transgen
key
modul
immun
respons
particular
chang
tropism
thu
interact
aav
particl
immun
cell
worth
note
although
natur
aav
serotyp
consid
unabl
effici
transduc
apc
particular
dc
current
unknown
interact
cell
final
import
highlight
strong
differ
among
aav
capsid
observ
murin
model
may
hold
true
anim
speci
particular
primat
even
natur
aav
vector
shown
induc
immun
respons
lead
elimin
transgeneexpress
cell
abil
aav
vector
effici
express
variou
transgen
includ
code
solubl
protein
foster
use
abgen
transfer
produc
neutral
ab
nab
directli
vivo
tabl
inde
abbas
therapi
costli
limit
halflif
ab
singl
administr
result
short
term
protect
therefor
therapi
requir
frequent
administr
rel
high
dose
ab
often
via
intraven
administr
sinc
high
persist
serum
level
ab
frequent
requir
optim
clinic
efficaci
scenario
use
aav
vector
may
great
interest
particular
allow
sustain
continu
express
ab
singl
administr
studi
gene
therapi
aav
vector
use
vehicl
produc
high
level
protein
vivo
contrast
previou
situat
activ
immunotherapi
immun
respons
transgen
product
ab
unwant
studi
perform
area
recent
use
natur
aav
serotyp
tabl
one
challeng
engin
aav
vector
code
full
length
ab
ensur
effici
equimolar
product
light
heavi
chain
major
advanc
achiev
demonstr
possibl
produc
high
level
ab
mice
intraport
administr
vector
express
heavi
light
chain
link
wwwfrontiersinorg
selfprocess
peptid
deriv
footandmouth
diseas
viru
technolog
mgml
ab
detect
serum
anim
sever
month
aav
administr
level
much
superior
previous
observ
use
vector
express
two
chain
use
dual
promot
system
initi
report
foster
seri
studi
valid
strategi
variou
experiment
model
notabl
use
specif
aav
serotyp
possibl
address
ab
secret
tissu
lung
site
entri
sever
virus
bacteria
exampl
intrapleur
administr
encod
murin
ab
respiratori
syncyti
viru
rsv
result
longterm
product
antirsv
nab
serum
lung
partial
protect
anim
challeng
viru
similar
strategi
develop
express
vivo
ab
abl
protect
deleteri
effect
induc
toxin
compound
anthrax
cocain
nicotin
use
aav
vehicl
gene
deliveri
induc
immun
respons
foreign
selfantigen
explor
anim
model
one
phase
clinic
trial
perform
human
prophylact
vaccin
infecti
agent
safeti
concern
sinc
typic
vaccin
given
healthi
children
adolesc
unknown
risk
late
consequ
also
prophylact
vaccin
often
target
larg
popul
standpoint
aav
vector
interest
tool
sinc
use
gene
therapi
alreadi
demonstr
overal
absenc
toxic
howev
current
high
cost
manufactur
aav
vector
need
high
particl
dose
clearli
major
hurdl
vaccin
develop
nevertheless
futur
studi
may
help
defin
nich
aav
may
particularli
advantag
vaccin
strategi
chapter
describ
number
inform
preclin
vaccin
studi
demonstr
complet
protect
experiment
challeng
relev
anim
model
andor
explor
effici
aavmedi
vaccin
nhp
nipah
viru
niv
hendra
viru
hev
close
relat
recent
emerg
paramyxovirus
belong
henipaviru
genu
virus
capabl
caus
consider
morbid
mortal
number
mammalian
speci
includ
human
infect
human
character
rapid
extens
spread
viru
sever
organ
symptom
includ
respiratori
distress
enceph
symptom
reproduc
experiment
infect
sever
anim
model
includ
hamster
high
pathogen
human
broad
tropism
absenc
vaccin
treatment
henipavirus
present
classifi
biosafeti
level
agent
consid
potenti
biothreat
major
vaccin
strategi
prevent
henipaviru
infect
focus
direct
administr
solubl
form
g
viral
glycoprotein
induc
protect
immun
respons
form
vaccin
requir
sever
inject
recombin
protein
coupl
adjuv
achiev
signific
immun
respons
recent
studi
ploquin
et
al
evalu
effici
aav
vector
express
niv
g
protein
induc
protect
immun
respons
evalu
two
rout
vaccin
differ
primeboost
strategi
employ
three
aav
serotyp
indic
singl
im
aav
inject
mice
suffici
induc
potent
long
last
ab
respons
consist
igg
nab
translat
studi
hamster
demonstr
singl
inject
aav
vector
encod
niv
g
suffici
protect
anim
lethal
challeng
niv
anim
challeng
hev
thu
indic
induct
crossneutr
immun
respons
altogeth
studi
present
new
vaccin
approach
wherebi
singl
immun
suffici
induct
protect
immun
henipavirus
open
new
perspect
toward
evalu
aav
vector
vaccin
emerg
infecti
diseas
control
epidem
hiv
infect
worldwid
remain
major
challeng
inde
even
though
signific
success
control
diseas
achiev
understand
viru
biolog
develop
target
drug
vaccinebas
prevent
measur
still
need
major
challeng
toward
goal
antigen
variabl
multitud
viru
strain
sever
viral
vector
test
vaccin
hiv
notabl
poxvirus
ad
met
littl
success
protect
efficaci
even
advers
effect
term
protect
hiv
infect
particular
case
step
human
trial
use
ad
vector
encod
hiv
protein
among
sever
vaccin
strategi
aav
vector
evalu
sever
anim
studi
tabl
earli
studi
aav
vector
express
hiv
env
tat
rev
gene
given
balbc
mice
singl
applic
differ
administr
rout
includ
intramuscular
intranas
result
product
high
level
hivspecif
serum
igg
fecal
secretori
iga
well
appear
cytotox
tcell
respons
noninvas
oral
administr
vector
express
hiv
env
gene
studi
xin
colleagu
show
induct
system
mucos
humor
cellular
immun
respons
partial
protect
rectal
challeng
recombin
vaccinia
viru
express
hiv
env
gene
advanc
studi
field
conduct
johnson
et
al
investig
efficaci
vector
express
sever
siv
gene
revgag
revenv
rtin
inject
intramuscularli
challeng
siv
studi
author
demonstr
induct
robust
cell
ab
respons
singl
vaccin
upon
challeng
siv
complet
protect
observ
low
dose
siv
given
intraven
howev
partial
protect
observ
higher
dose
siv
note
one
phase
trial
demonstr
safeti
modest
immunogen
gagspecif
cell
recipi
much
interest
perspect
field
provid
two
recent
studi
use
aav
vector
passiv
immunotherapi
tabl
concept
first
valid
johnson
colleagu
use
vector
express
imunoadhesin
ia
siv
macaqu
ia
chimer
ablik
molecul
gener
compos
fc
region
immunoglobulin
link
ligandbind
region
receptor
adhes
molecul
ia
offer
advantag
small
molecul
whose
sequenc
easili
accommod
aav
vector
eventu
scaav
vector
packag
doublestrand
dna
genom
enhanc
kinet
level
transgen
express
johnson
colleagu
demonstr
intramuscular
inject
vector
result
higher
level
secret
ia
use
convent
ss
gener
long
last
neutral
activ
serum
importantli
vaccin
anim
protect
infect
siv
protect
diseas
howev
ab
ia
gener
anim
correl
partial
protect
potenti
aavbas
passiv
immunotherapi
hiv
infect
demonstr
balaz
colleagu
report
lifelong
express
mice
monoclon
ab
hiv
singl
intramuscular
inject
vector
importantli
human
mice
vaccin
aav
protect
intraven
inject
replic
compet
hiv
high
dose
two
vlpsbase
vaccin
commerci
avail
hpv
hpv
import
risk
factor
develop
cervic
cancer
malign
tumor
anogenit
tract
head
neck
clinic
trial
first
report
launch
vaccin
campaign
demonstr
highli
effici
protect
persist
infect
precancer
lesion
besid
excel
safeti
profil
review
see
ref
earli
data
influenc
vaccin
strategi
cancer
incid
expect
aris
year
initi
mass
immun
despit
high
cost
avail
product
near
futur
aavbas
hpv
vaccin
unlik
becom
seriou
contend
exist
vaccin
scheme
involv
three
im
inject
adjuv
vlp
manufactur
recombin
express
hpv
major
structur
protein
yet
studi
hpv
aav
yield
interest
result
mice
nhp
make
vector
interest
option
futur
develop
exampl
kuck
colleagu
demonstr
sustain
humor
cellular
immun
respons
year
mice
immun
singl
intranas
dose
respons
far
outlast
one
obtain
three
dose
hpv
vlp
appli
rout
lyophil
redissolv
aav
particl
remain
immunogen
albeit
reduc
effici
thu
aav
potenti
needleless
vaccin
unlik
avail
vaccin
need
refriger
sinc
store
lyophil
powder
featur
import
develop
countri
cervic
cancer
major
public
health
challeng
intranas
immun
also
test
nhp
macaqu
nab
elicit
persist
least
month
post
aav
administr
expect
previou
studi
presenc
preexist
high
titer
ab
prevent
immun
serotyp
administ
intranas
mention
introduct
prophylact
hpv
vaccin
potenti
significantli
reduc
worldwid
burden
hpvrelat
diseas
howev
even
countri
suffici
resourc
alway
individu
reason
ignor
hpv
human
carcinogen
activ
object
vaccin
per
se
benefit
program
therefor
medic
need
develop
hpvspecif
therapeut
vaccin
establish
infect
strategi
involv
cytotox
cell
earli
protein
express
persist
infect
hpvtransform
cell
review
see
ref
one
intens
studi
target
name
viral
oncoprotein
also
analyz
transgen
aav
vector
tabl
two
studi
use
aav
vector
code
aa
hpv
peptid
contain
welldefin
mous
restrict
ctl
epitop
complet
hpv
gene
fuse
mycobacterium
tuberculosi
heat
shock
protein
singl
intramuscular
immun
mice
induc
lymphocyt
upon
challeng
syngen
cell
signific
delay
complet
inhibit
tumor
growth
experi
aim
toward
hpv
vaccin
combin
prophylact
therapeut
properti
nieto
colleagu
analyz
differ
aav
serotyp
carri
fusion
gene
major
part
singl
intranas
immun
mice
vector
effici
induc
humor
cellular
immun
respons
superior
vaccin
vlp
chimer
vlp
addit
vaccin
aav
vector
led
signific
protect
anim
challeng
differ
hpv
tumor
cell
line
current
avail
vaccin
insuffici
keep
check
season
influenza
outbreak
affect
peopl
age
claim
least
one
million
live
children
year
age
worldwid
reason
vaccin
rel
less
success
high
variabl
viru
highli
typespecif
natur
vaccin
need
design
actual
emerg
viru
strain
unavoid
delay
identif
new
variant
avail
appropri
vaccin
particularli
owe
labori
manufactur
process
viru
replic
chicken
egg
leav
popul
unprotect
least
first
wave
new
epidem
earlier
studi
demonstr
strainspecif
immun
protect
lethal
challeng
sipo
colleagu
gener
vector
express
hemagglutinin
ha
nucleoprotein
np
matrix
protein
gene
isol
pandem
influenza
swine
origin
singl
inject
mixtur
two
three
aav
serotyp
obtain
complet
protect
homolog
challeng
partial
protect
heterolog
highli
virul
strain
author
argu
although
vaccin
candid
induc
steril
immun
may
mitig
clinic
symptom
diminish
transmiss
rate
thu
gener
herd
immun
homolog
classic
vaccin
made
avail
slightli
recent
studi
also
examin
protect
level
wwwfrontiersinorg
mice
vaccin
aav
vector
express
np
particular
object
studi
evalu
efficaci
protect
mice
receiv
high
dose
pool
human
igg
mimic
situat
preexist
immun
aav
may
interfer
vaccin
interestingli
studi
author
show
vectorexpress
np
could
fulli
protect
anim
challeng
lethal
dose
influenza
viru
strain
altogeth
studi
demonstr
effici
strainspecif
aav
vaccin
howev
rna
virus
vaccin
season
influenza
outbreak
complic
continu
emerg
new
variant
strain
escap
nab
gener
previou
infect
recent
isol
crossneutr
ab
bind
conserv
region
ha
recent
allow
evalu
new
vaccin
strategi
base
passiv
immunotherapi
aim
gener
longterm
broadli
protect
humor
activ
vivo
interestingli
two
independ
group
simultan
report
use
aav
vector
produc
vivo
either
full
length
human
ab
ha
ia
direct
protein
first
studi
author
inject
vector
intramuscularli
mice
ferret
demonstr
longterm
product
antiha
ab
serum
confer
complet
protect
five
differ
influenza
strain
second
studi
vector
administ
intranas
induc
product
ia
nose
lung
advantag
mode
deliveri
vector
express
local
nasal
epithelia
expect
wide
dissemin
bodi
addit
natur
turnov
airway
epitheli
cell
may
ensur
vector
perman
present
vivo
first
studi
anim
protect
challeng
differ
influenza
strain
importantli
latter
exampl
author
also
show
time
aav
inject
challeng
could
reduc
day
demonstr
potenc
express
system
howev
studi
analys
perform
larger
anim
speci
particular
ferret
result
partial
protect
probabl
emerg
immun
respons
human
ab
ia
cours
immun
respons
human
ab
expect
human
whether
hold
true
ia
still
unclear
even
though
import
issu
potenti
immunogen
ia
translat
approach
larger
anim
still
need
improv
approach
clearli
indic
aav
vector
power
tool
passiv
immunotherapi
certainli
deserv
studi
nhp
model
studi
conduct
far
highlight
sever
import
advantag
aav
vector
vaccin
notabl
case
activ
immunotherapi
capac
induc
sustain
level
ab
respons
singl
inject
passiv
immunotherapi
tool
secret
ab
directli
circul
featur
link
capac
aav
vector
persist
long
period
transduc
tissu
clearli
distinguish
aav
viral
vector
ad
poxvirus
rapid
elimin
transduc
cell
observ
vivo
despit
properti
mani
drawback
still
hamper
use
vector
vaccin
human
last
section
review
major
problem
remain
solv
discuss
possibl
solut
rational
use
aav
vector
genet
vaccin
mainli
base
intrins
absenc
pathogen
capac
infect
varieti
tissu
express
transgen
high
sustain
level
use
aav
passiv
immunotherapi
properti
suffici
consid
aav
vector
promis
tool
even
though
safeti
studi
requir
evalu
effect
continu
secret
ab
vivo
howev
case
activ
immunotherapi
properti
may
alway
suffici
ensur
effici
vaccin
inde
even
shown
capabl
induc
transgenespecif
immun
respons
larg
anim
model
activ
innat
respons
modest
detect
level
aav
vector
still
consid
possess
low
immunogen
profil
compar
viral
vector
particular
ad
vector
notabl
illustr
persist
transgen
express
observ
sever
vaccin
studi
report
lack
function
tcell
respons
observ
natur
aav
serotyp
aspect
clearli
repres
major
disadvantag
use
aav
prevent
therapeut
vaccin
trial
requir
induct
robust
cytotox
tcell
respons
therefor
use
vector
applic
requir
enhanc
intrins
immunogen
properti
sever
studi
alreadi
indic
possibl
notabl
manipul
viral
genom
capsid
adenoassoci
viru
vector
compos
ss
sc
dna
genom
chang
natur
dna
genom
profound
impact
kinet
level
transgen
express
bypass
need
dna
secondstrand
synthesi
transcript
vector
cassett
accordingli
comparison
ss
scaav
vector
passiv
immunotherapi
indic
latter
produc
higher
level
ab
former
interestingli
sever
recent
studi
indic
modif
could
also
impact
immunogen
properti
vector
inde
modifi
vector
backbon
enhanc
innat
transgenespecif
adapt
immun
respons
particular
use
aav
vector
express
secret
version
hiv
gag
protein
wu
colleagu
show
scaav
vector
differ
serotyp
induc
potent
tcell
ab
respons
convent
ssaav
howev
previous
observ
convent
ssaav
vector
progress
loss
function
cell
observ
indic
modif
natur
vector
genom
suffici
gener
fulli
function
tcell
respons
addit
strategi
applic
transgen
could
accommod
express
cassett
one
half
convent
aav
vector
anoth
strategi
enhanc
transgenespecif
immun
respons
induc
aav
consist
chang
viral
capsid
obvious
frontier
immunolog
microbi
immunolog
level
natur
immun
respons
tightli
link
natur
capsid
determin
tropism
particl
effici
transduct
accordingli
sever
studi
document
signific
differ
level
immun
respons
induc
natur
aav
serotyp
present
aav
variant
isol
human
nonhuman
tissu
approxim
use
produc
vector
even
greater
varieti
offer
possibl
genet
modifi
capsid
either
creat
artifici
variant
insert
specif
immunogen
peptid
capsid
surfac
discuss
regard
gener
new
artifici
aav
variant
compel
evid
provid
studi
perform
variant
engin
hybrid
two
natur
aav
rhesu
macaqu
isol
specif
select
immunogen
properti
analysi
immun
respons
induc
variant
indic
abl
induc
vibrant
function
tcell
respons
direct
ag
unlik
natur
aav
serotyp
exploit
capac
benefici
vaccin
develop
recent
structur
analysi
variant
indic
function
tcell
activ
domain
lie
within
portion
capsid
futur
deeper
understand
immunolog
properti
capsid
domain
aav
may
lead
ration
design
artifici
variant
capabl
differenti
stimul
immun
respons
interest
strategi
increas
aav
immunogen
focus
gener
capsid
expos
select
epitop
aav
particl
compos
capsid
protein
subunit
name
effici
method
gener
genet
modifi
capsid
expos
select
peptid
develop
recent
year
due
highli
structur
repetit
present
epitop
capsid
potent
bcell
respons
peptid
expect
two
recent
studi
illustr
feasibl
approach
nieto
colleagu
insert
two
neutral
epitop
protein
two
differ
posit
use
assembl
empti
aav
particl
aavlp
vaccin
mice
rabbit
aavlp
empti
particl
coupl
montanid
adjuv
induc
high
level
ab
abl
cross
neutral
sever
hpv
type
similar
approach
rybnik
colleagu
use
genet
modifi
capsid
display
surfac
well
describ
ag
tuberculosi
use
modifi
capsid
packag
vector
overexpress
ag
increas
kinet
ab
product
well
avid
compar
aav
assembl
wild
type
capsid
addit
insert
antigen
capsid
surfac
also
shown
suffici
induc
memori
bcell
recal
respons
strategi
illustr
potenti
capsid
modif
manipul
immun
respons
like
near
futur
new
aav
vector
specif
select
abil
induc
strong
transgenespecif
immun
respons
continu
emerg
epidemiolog
studi
indic
antiaav
ab
detect
major
popul
worldwid
seropreval
vari
accord
aav
serotyp
geograph
region
review
see
ref
result
efficaci
aav
vector
vivo
gene
transfer
sever
reduc
anim
model
use
altern
aav
serotyp
suffici
circumv
antiaav
nab
induc
previou
immun
differ
capsid
howev
strategi
may
valid
human
potenti
wider
crossreact
immun
respons
exist
interestingli
howev
artifici
variant
show
much
lower
seropreval
natur
serotyp
less
popul
test
posit
worldwid
indic
could
repres
good
candid
vaccin
addit
strategi
circumv
preexist
immun
provid
possibl
engin
aav
capsid
mutat
target
key
immunogen
amino
acid
sophist
strategi
develop
maersch
colleagu
demonstr
feasibl
use
vitro
direct
evolut
method
select
aav
particl
capabl
escap
nab
gene
therapi
trial
use
aav
vector
human
requir
high
vector
dose
order
achiev
therapeut
effici
exampl
dose
approxim
vector
particl
per
kilogram
requir
initi
hemophilia
b
trial
use
vector
even
lower
dose
use
latter
trial
use
aav
serotyp
amount
particl
deliv
singl
inject
patient
still
remain
impress
high
experi
perform
anim
vaccin
aav
also
use
high
dose
achiev
effici
immun
respons
therefor
gene
therapi
applic
high
vector
dose
may
constitut
safeti
concern
increas
risk
induc
detriment
immun
respons
offtarget
transduct
henc
futur
effort
reduc
vector
dose
focu
decreas
vector
load
improv
transduct
effici
increas
immunogen
vector
particl
